OpenAI took its biggest step yet into the life sciences sector on April 16 and 17, 2026, launching GPT-Rosalind - a specialized reasoning model built for biology, drug discovery, and translational medicine research.
OpenAI designed GPT-Rosalind to be better at fundamental reasoning in fields like biochemistry and genomics. The company says the models won't replace scientists, but rather help them move faster through some of the most time-intensive and analytically demanding work of the scientific process. Axios
The name is a nod to Rosalind Franklin, the British chemist whose X-ray crystallography work helped reveal the structure of DNA.
The Problem OpenAI Is Targeting
It currently takes roughly 10 to 15 years to go from target discovery to regulatory approval for new drugs in the U.S. Only one in 10 drugs entering clinical trials ultimately gets approved. More than 30 million Americans and 300 million people globally living with rare diseases are waiting for better treatments. Axios
Those numbers frame why pharma companies are pouring resources into AI. GPT-Rosalind is OpenAI's direct play for that market.
Who Has Access
The model is designed to help researchers with early-stage drug discovery by making evidence synthesis, hypothesis generation, and experimental planning quicker and more efficient. OpenAI is already working with Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific to apply it to research and discovery workflows. pharmaphorum
Access is gated through a trusted-access program - only organizations conducting legitimate scientific research with clear public benefits can apply. The model is also available through a free Life Sciences research plugin for Codex, which connects to over 50 scientific tools and data sources.
The Competitive Reaction
Drug discovery AI companies felt the news immediately. After the announcement, shares of several drug discovery companies dropped. Recursion Pharmaceuticals and Schrodinger each lost more than 5% of their value, IQVIA Holdings fell by up to 3.2%, and Charles River Laboratories dropped by 2.6%. Quartz
That reaction tells you what the market thinks about what OpenAI entering this space means for incumbents.
What This Means for Your Business
If you're in life sciences, healthcare, or pharma - or you advise companies in those sectors - GPT-Rosalind signals that general-purpose AI labs are coming for vertical use cases. This is not a distant threat. OpenAI already has Amgen and Moderna running pilots today. For AI strategy conversations at the executive level, the question is shifting from "should we use AI for drug discovery" to "which platform do we build on."
